PUBLICATION

Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition

Authors
Potts, K.S., Cameron, R.C., Metidji, A., Ghazale, N., Wallace, L., Leal-Cervantes, A.I., Palumbo, R., Barajas, J.M., Gupta, V., Aluri, S., Pradhan, K., Myers, J.A., McKinstry, M., Bai, X., Choudhary, G.S., Shastri, A., Verma, A., Obeng, E.A., Bowman, T.V.
ID
ZDB-PUB-221216-16
Date
2022
Source
Cell Reports   41: 111825111825 (Journal)
Registered Authors
Bowman, Teresa
Keywords
CP: Molecular biology, CP: Stem cell research, SF3B1, STAT3, hematopoietic stem and progenitor cell, myelodysplastic syndrome, splicing factor, zebrafish
Datasets
GEO:GSE206021, GEO:GSE206017, GEO:GSE206019
MeSH Terms
  • Animals
  • Hematopoiesis*/genetics
  • Hematopoietic Stem Cells/metabolism
  • Humans
  • Mice
  • Mutation/genetics
  • Phosphoproteins/metabolism
  • RNA Splicing/genetics
  • RNA Splicing Factors/genetics
  • RNA Splicing Factors/metabolism
  • STAT3 Transcription Factor/genetics
  • Zebrafish*/metabolism
PubMed
36516770 Full text @ Cell Rep.
Abstract
Hematopoietic stem and progenitor cells (HSPCs) sustain lifelong hematopoiesis. Mutations of pre-mRNA splicing machinery, especially splicing factor 3b, subunit 1 (SF3B1), are early lesions found in malignancies arising from HSPC dysfunction. However, why splicing factor deficits contribute to HSPC defects remains incompletely understood. Using zebrafish, we show that HSPC formation in sf3b1 homozygous mutants is dependent on STAT3 activation. Clinically, mutations in SF3B1 are heterozygous; thus, we explored if targeting STAT3 could be a vulnerability in these cells. We show that SF3B1 heterozygosity confers heightened sensitivity to STAT3 inhibition in zebrafish, mouse, and human HSPCs. Cells carrying mutations in other splicing factors or treated with splicing modulators are also more sensitive to STAT3 inhibition. Mechanistically, we illustrate that STAT3 inhibition exacerbates aberrant splicing in SF3B1 mutant cells. Our findings reveal a conserved vulnerability of splicing factor mutant HSPCs that could allow for their selective targeting in hematologic malignancies.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping